Menu
Home
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Home
Forums
Labrish
Nyuuz
Shkreli Goes Ballistic on FDA Chief Prasad
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
[QUOTE="Munyaradzi Mafaro, post: 37112, member: 636"] Martin Shkreli, once called America's most hated executive after raising prices on a key medicine, has gained many followers on X with his sharp pharma comments. He recently attacked Vinay Prasad, the new FDA Center for Biologics leader, calling him "nuts" with "no idea" about how the drug industry works. Prasad, an oncologist known for opposing COVID-19 booster shots, wrote that more testing should happen before changing vaccine rules. Shkreli claims he talked with leaders of almost every major drug company recently, warning they might fail under Prasad's leadership. He fears stricter testing rules will harm companies already facing tough competition. Bristol Myers Squibb laid off 516 workers last month, bringing this year's total to 806 after cutting 2,200 jobs last year. Some see Shkreli's criticism as proof Prasad stands up to drug companies, but others view it as a warning about industry troubles. The debate raises questions about whether struggling companies should survive or fail as part of normal market forces. [/QUOTE]
Insert quotes…
Name
Post reply
Home
Forums
Labrish
Nyuuz
Shkreli Goes Ballistic on FDA Chief Prasad
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top